Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04612790
Registration number
NCT04612790
Ethics application status
Date submitted
12/10/2020
Date registered
3/11/2020
Date last updated
18/11/2023
Titles & IDs
Public title
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
Query!
Scientific title
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)
Query!
Secondary ID [1]
0
0
2023-505033-27-00
Query!
Secondary ID [2]
0
0
D325AC00002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FJORD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Bullous Pemphigoid
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Benralizumab
Other interventions - Placebo
Experimental: Benralizumab - Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.
Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Experimental: Placebo - Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Other interventions: Benralizumab
Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.
Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Other interventions: Placebo
Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of participants who are in complete remission while off OCS for = 2 months at Week 36 (FAS)
Query!
Assessment method [1]
0
0
A binary response, whereby a responder is defined as a participant who is in complete remission while off OCS for = 2 months at Week 36. Otherwise, a participant is a non-responder.
Query!
Timepoint [1]
0
0
Week 36
Query!
Secondary outcome [1]
0
0
Proportion of participants who remain relapse-free up to Week 36.
Query!
Assessment method [1]
0
0
Relapse is defined as participants experiencing: 3 or more new lesions a per month (blisters, eczematous lesions, or urticarial plaques); or at least one large (> 10 cm diameter) eczematous lesion or urticarial plaques that do not heal within 1 week; or the extension of established lesions or daily pruritus in participants who have achieved disease control.
Query!
Timepoint [1]
0
0
Week 36
Query!
Secondary outcome [2]
0
0
Cumulative OCS exposure (mg/kg) from baseline to Week 36.
Query!
Assessment method [2]
0
0
For each 4 weekly interval and for the sum of the 4-weekly intervals over the whole of the 36-week treatment period, and for the sum of the 4-weekly intervals over the initial 16-week treatment period, the model will be used to estimate the mean cumulative OCS exposure (mg/kg) for each treatment group and the difference versus placebo, with corresponding 95% confidence limits.
Query!
Timepoint [2]
0
0
Week 36
Query!
Secondary outcome [3]
0
0
Change from baseline in BPDAI activity score at Week 36.
Query!
Assessment method [3]
0
0
Bullous Pemphigoid Disease Area Index is a clinician completed tool that is used for independent disease severity assessment to measure disease extent in BP. The BPDAI total activity and BPDAI damage give an indication of disease activity, with higher scores indicating greater disease activity or damage.
Query!
Timepoint [3]
0
0
Week 36
Query!
Secondary outcome [4]
0
0
Change from baseline in BPDAI-Pruritus score at Week 36.
Query!
Assessment method [4]
0
0
The BPDAI-Pruritus is a separate component of the BPDAI that asks the participant to grade the severity of pruritus over the past 24 hours, the past week, and the past month. For each recall period, severity of pruritus is rated on an NRS ranging from 0 for no itch to 10 for maximal itching. The three scores are then summed for a total score ranging from 0 to 30.
Query!
Timepoint [4]
0
0
Week 36
Query!
Secondary outcome [5]
0
0
Proportion of participants in sustained complete/ partial remission on minimal OCS/ off OCS for at least 2 months at week 36
Query!
Assessment method [5]
0
0
Sustained complete remission on minimal steroid therapy/off steroid therapy. The absence of new or established lesions or pruritus while the participant is on minimal steroid therapy/ off steroid therapy for at least 2 months:
Sustained partial remission: the presence of transient new lesions that heal within 1 week while the participant is on minimal steroid therapy or off steroid therapy for at least 2 months.
Query!
Timepoint [5]
0
0
Week 36
Query!
Secondary outcome [6]
0
0
Cumulative time (weeks) in complete remission off OCS from baseline to Week 36
Query!
Assessment method [6]
0
0
Complete remission off steroid therapy is defined as the absence of new or established lesions or pruritus while the participant is off steroid therapy for at least 2 months.
Query!
Timepoint [6]
0
0
Week 36
Query!
Secondary outcome [7]
0
0
Proportion of participants off OCS by Week 36.
Query!
Assessment method [7]
0
0
The consolidation phase begins when disease control is achieved and continues until the time at which no new lesions or pruritic symptoms have developed for a minimum of 2 weeks and the majority of established lesions have healed (end of consolidation phase). At this point, participants will begin protocolled OCS tapering, with the aim to taper off OCS completely within 3 to 4 months (ie, 4 to 5 months from randomization).
Query!
Timepoint [7]
0
0
Week 36
Query!
Secondary outcome [8]
0
0
IGA Score at Week 36.
Query!
Assessment method [8]
0
0
An IGA scale uses clinical characteristics to assess overall disease severity at any given time point. This scoring system allows clinicians to rate skin disease activity by general overall impressions. This IGA scale uses key signs of BP with ordinal levels of severity. The IGA is a 5-point categorical scale ranging from 0 (clear) to 4 (severe) with higher scores indicating greater disease activity or damage. The IGA uses clinical characteristics based on the number of lesions, blisters, erosions, erythema and number of anatomical locations.
Query!
Timepoint [8]
0
0
Week 36
Query!
Secondary outcome [9]
0
0
Change from baseline in IGA score at Week 36.
Query!
Assessment method [9]
0
0
An IGA scale uses clinical characteristics to assess overall disease severity at any given time point. This scoring system allows clinicians to rate skin disease activity by general overall impressions. This IGA scale uses key signs of BP with ordinal levels of severity. The IGA is a 5-point categorical scale ranging from 0 (clear) to 4 (severe) with higher scores indicating greater disease activity or damage .The IGA uses clinical characteristics based on the number of lesions, blisters, erosions, erythema and number of anatomical locations
Query!
Timepoint [9]
0
0
Week 36
Query!
Secondary outcome [10]
0
0
Cumulative OCS exposure (mg/kg) from baseline to Week 16.
Query!
Assessment method [10]
0
0
For each 4 weekly interval and for the sum of the 4-weekly intervals over the whole of the 36-week treatment period, and for the sum of the 4-weekly intervals over the initial 16-week treatment period, the model will be used to estimate the mean cumulative OCS exposure (mg/kg) for each treatment group and the difference versus placebo, with corresponding 95% confidence limits.
Query!
Timepoint [10]
0
0
Week 16
Query!
Secondary outcome [11]
0
0
Proportion of participants who remain relapse-free up to Week 16.
Query!
Assessment method [11]
0
0
Relapse is defined as participants experiencing: 3 or more new lesions a per month (blisters, eczematous lesions, or urticarial plaques); or at least one large (> 10 cm diameter) eczematous lesion or urticarial plaques that do not heal within 1 week; or the extension of established lesions or daily pruritus in participants who have achieved disease control.
Query!
Timepoint [11]
0
0
Week 16
Query!
Secondary outcome [12]
0
0
Proportion of participants with any clinical benefit (eg, partial and complete remission during taper, with no steroid use, or with minimal steroid use [ie, < 0.1 mg/kg/day]) at Week 16.
Query!
Assessment method [12]
0
0
To assess partial and complete remission during taper, with no steroid use, or with minimal steroid use at week 16)
Query!
Timepoint [12]
0
0
Week 16
Query!
Secondary outcome [13]
0
0
Time to disease control, OCS dose (mg/kg) at disease control and time to the end of the consolidation phase.
Query!
Assessment method [13]
0
0
The time at which new lesions cease to form and established lesions begin to heal or pruritic symptoms start to abate.
During the first 8 weeks of the study, participants will be assessed every 2 weeks for disease Control. When disease control is achieved, this marks the beginning of the consolidation phase. The end of the consolidation phase is the point that corticosteroid tapering will be initiated.
Query!
Timepoint [13]
0
0
Week 16
Query!
Secondary outcome [14]
0
0
Change from baseline in BPDAI activity score at Week 16.
Query!
Assessment method [14]
0
0
The total BPDAI activity score (0 to 360) is the arithmetic sum of the 3 subcomponents - cutaneous blisters/ erosions, cutaneous urticarial/ erythema, and mucosal blisters/ erosions
Query!
Timepoint [14]
0
0
Week 16
Query!
Secondary outcome [15]
0
0
Change from baseline in BPDAI-Pruritus score at Week 16.
Query!
Assessment method [15]
0
0
The BPDAI-Pruritus is a separate component of the BPDAI that asks the participant to grade the severity of pruritus is rated on an NRS ranging from 0 to no itch to 10 for maximal itching.
Query!
Timepoint [15]
0
0
Week 16
Query!
Secondary outcome [16]
0
0
Serum benralizumab concentration.
Query!
Assessment method [16]
0
0
To estimate the PK of benralizumab in participants with BP.
Query!
Timepoint [16]
0
0
Weeks 0,2,4,6,8,16,24,36, 60 and 12 weeks after last IP dose
Query!
Secondary outcome [17]
0
0
Determination of Anti-drug antibodies (ADA) in serum
Query!
Assessment method [17]
0
0
Blood samples for determination of ADA in serum will be assayed to assess immunogenicity of benralizumab.
Query!
Timepoint [17]
0
0
Weeks 0,4,6,8,16,24,36, 60 and 12 weeks after last IP dose
Query!
Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria
apply:
Informed Consent/Age
1. Capable of giving signed informed consent as described in Appendix A which includes
compliance with the requirements and restrictions listed in the ICF and in this
protocol.
2. Adult participants = 18 years of age at the time of signing the ICF.
Type of Participant and Disease Characteristics
3. Participants must have clinical features of BP (eg, urticarial or eczematous or
erythematous plaques, bullae, pruritus) at the screening visit and confirmed diagnosis
with histology, direct immunofluorescence, and serology at randomization. Required for
inclusion:
1. Histology.
2. Positive direct immunofluorescence (from skin biopsy) (IgG and/or C3 at the
basement membrane zone).
3. AND at least one of the following serologic assessments positive (all assessed
from participant's blood sample):
(i) indirect immunofluorescence (IgG on the roof of salt- split skin). (ii) positive
serology on ELISA for BPAG1 (230-kd). (iii) positive serology on ELISA for BPAG2
(180-kd).
4. BPDAI activity score = 24 at the screening and randomization visits.
5. Candidate for systemic corticosteroid therapy.
6. Able to complete PRO assessments on a tablet and on a handheld device. Some
participants may be exempted from completing home PROs on the handheld device upon
agreement with the AstraZeneca physician (eg, if the patient has a medical condition
such as BP lesions of the fingers/hand, a neurologic condition affecting fingers/hand,
or severe visual impairment).
Sex 7 Male or female.
Reproduction 8 Female participants capable of having children must meet both of the
following conditions ([a] and [b]):
(a) Have a negative urine pregnancy test at screening and (b) Must agree to use a highly
effective method of birth control (confirmed by the investigator) from randomization
throughout the study duration and within 12 weeks after last dose of IP. Highly effective
forms (those that can achieve a failure rate of less than 1% per year when used
consistently and correctly) of birth control include: (i) Combined (estrogen and
progestogen containing) hormonal contraception associated with inhibition of ovulation -
oral, intravaginal, or transdermal.
(ii) Progestogen-only hormonal contraception associated with inhibition of ovulation -
oral, injectable, or implantable.
(iii) Intrauterine device. (iv) Intrauterine hormone-releasing system. (v) Bilateral tubal
occlusion. (vi) Sexual abstinence, ie, refraining from heterosexual intercourse (the
reliability of sexual abstinence needs to be evaluated in relation to the duration of the
clinical study and the preferred and usual lifestyle of the participant).
(vii) Vasectomized sexual partner provided that partner is the sole sexual partner of the
female of childbearing potential (FOCBP) study participant and that the vasectomized
partner has received medical assessment of the surgical success.
(c) Females not of childbearing potential are defined as females who are either permanently
sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are
postmenopausal. Females will be considered postmenopausal if they have been amenorrhoeic
for = 12 months prior to the planned date of randomization without an alternative medical
cause. The following age-specific requirements apply: (i) Females < 50 years old will be
considered postmenopausal if they have been amenorrhoeic for 12 months or more following
cessation of exogenous hormonal treatment and follicle-stimulating hormone (FSH) levels in
the postmenopausal range. Until FSH is documented to be within menopausal range, treat the
participant as a female of childbearing potential.
(ii) Females = 50 years old will be considered postmenopausal if they have been
amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
130
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1. Forms of BP other than classic, predominantly cutaneous BP: eg, mucous membrane BP,
epidermolysis bullosa acquisita, Brunsting-Perry BP, p200 BP, p105 BP, BP with
concomitant pemphigus vulgaris, and drug-induced BP.
2. Comorbid disease that in the Investigator's judgement might interfere with the
evaluation of the IP or safety of the participant. This includes any disorder that in
the opinion of the Investigator is not stable (eg, cardiovascular, gastrointestinal,
hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
hematological, psychiatric, or major physical impairment).
3. Current or history of malignancy within 5 years before the screening visit with the
following exceptions:
1. Participants treated for in situ carcinoma of the cervix who have completed
curative therapy and are in remission for at least 12 months prior to signing the
informed consent and
2. Participants with superficial basal cell or squamous skin cancer.
3. Participants who have had other malignancies are eligible provided that the
participant is in remission and curative therapy was completed at least 5 years
prior to the date informed consent was obtained.
4. History of anaphylaxis to any biologic therapy or vaccine.
5. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed
consent is obtained that has not been treated with, or has failed to respond to
standard of care therapy.
6. Any clinically significant abnormal findings in physical examination, vital signs,
electrocardiogram (ECG), hematology, or clinical chemistry during screening, which in
the opinion of the Investigator, may put the participant at risk because of his/her
participation in the study, or may influence the results of the study.
7. Current active liver disease.
1. Chronic stable hepatitis B and C (including positive testing for hepatitis B
surface antigen or hepatitis C antibody), or other stable chronic liver disease
are acceptable if participant otherwise meets eligibility criteria. Stable
chronic liver disease should generally be defined by the absence of ascites,
encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or
persistent jaundice, or cirrhosis.
2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level =3 times
the upper limit of normal, confirmed by repeated testing during screening period.
Transient increase of AST/ALT level that resolves by the time of randomization is
acceptable if in the Investigator's opinion the participant does not have an
active liver disease and meets other eligibility criteria.
8. A history of known immunodeficiency disorder including a positive human
immunodeficiency virus (HIV) test.
Prior/Concomitant Therapy
9. Use of immunosuppressive medication, including, but not limited to: methotrexate,
cyclosporine, azathioprine, within 4 weeks or 5 half-lives prior to the date informed
consent is obtained, whichever is longer.
Other Exclusions
10. Receipt of immunoglobulin or blood products within 30 days prior to the date informed
consent is obtained.
11. Receipt of any marketed or investigational biologic within 4 months or 5 half-lives
prior to the date informed consent is obtained, whichever is longer. Participants on
stable therapy for at least 3 months before randomization who intend to stay on
treatment throughout the study with marketed biologics that are not likely to
interfere with the assessment of safety and/or efficacy of benralizumab (eg, for the
treatment of osteoporosis, migraine, pain, diabetes, obesity, ocular, cardiovascular,
or metabolic diseases) can participate in the study.
12. Known history of allergy or reaction to any component of the IP formulation.
13. Receipt of live attenuated vaccines 30 days prior to the date of randomization.
14. Previously received benralizumab (MEDI-563, FASENRA).
15. Change to allergen immunotherapy or new allergen immunotherapy within 30 days prior to
the date of informed consent and anticipated changes in immunotherapy throughout the
study.
16. Planned elective major surgical procedures during the conduct of the study.
17. Previous randomization in the present study.
18. Concurrent enrollment in another interventional (eg, investigational drug or device)
clinical trial.
19. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
staff and/or staff at the study site).
20. For females only: Currently pregnant, breastfeeding, or lactating females.
(a) A urine pregnancy test must be performed for FOCBP at Visit 1. A positive urine
test result must be confirmed with a serum pregnancy test. If serum test is positive,
the participant should be excluded.
21. Participant is unable to complete PRO assessments because of cognitive function (eg,
dementia).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/03/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/10/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
67
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Kogarah
Query!
Recruitment hospital [2]
0
0
Research Site - Parkville
Query!
Recruitment hospital [3]
0
0
Research Site - Westmead
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
Bulgaria
Query!
State/province [6]
0
0
Haskovo
Query!
Country [7]
0
0
Bulgaria
Query!
State/province [7]
0
0
Sofia
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Beijing
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Guangzhou
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Hohhot
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Shanghai
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Lille Cedex
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Marseille
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Nice
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Rouen Cedex
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Bad Bentheim
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Bielefeld
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Dresden
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Leipzig
Query!
Country [20]
0
0
Greece
Query!
State/province [20]
0
0
Thessaloniki
Query!
Country [21]
0
0
Israel
Query!
State/province [21]
0
0
Ramat Gan
Query!
Country [22]
0
0
Israel
Query!
State/province [22]
0
0
Tel-Aviv
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Catania
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
Florence
Query!
Country [25]
0
0
Italy
Query!
State/province [25]
0
0
Rome
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Iruma-Gun
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Kitakyusyu-shi
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Kurume-shi
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Okayama
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Ota-ku
Query!
Country [31]
0
0
Japan
Query!
State/province [31]
0
0
Sapporo-shi
Query!
Country [32]
0
0
Japan
Query!
State/province [32]
0
0
Urayasu-shi
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Alicante
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Madrid
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to investigate the use of benralizumab is effective in the
treatment of patients symptomatic Bullous Pemphigoid (BP).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04612790
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04612790
Download to PDF